Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0B5EB
|
||||
| Former ID |
DIB011699
|
||||
| Drug Name |
Ponezumab
|
||||
| Synonyms |
Neurological disease and injury therapeutics, Pfizer; PF-04360365; PF-4360365; RI-1014; RI-1219; RI-409; RN-1219
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Alzheimer disease [ICD9: 331; ICD10:G30] | Phase 2 | [1] | ||
| Company |
Rinat Neuroscience Corp
|
||||
| CAS Number |
CAS 1178862-65-1
|
||||
| Target and Pathway | |||||
| Target(s) | Amyloid beta A4 protein | Target Info | [2] | ||
| KEGG Pathway | Notch signaling pathway | ||||
| Alzheimer's disease | |||||
| Reactome | Nuclear signaling by ERBB4 | ||||
| Degradation of the extracellular matrix | |||||
| Regulated proteolysis of p75NTR | |||||
| NRIF signals cell death from the nucleus | |||||
| Activated NOTCH1 Transmits Signal to the Nucleus | |||||
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | |||||
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | |||||
| EPH-ephrin mediated repulsion of cells | |||||
| WikiPathways | Notch Signaling Pathway | ||||
| Signaling by ERBB4 | |||||
| Signaling by NOTCH3 | |||||
| Signaling by NOTCH4 | |||||
| Signaling by NOTCH1 | |||||
| Signaling by NOTCH2 | |||||
| Notch Signaling Pathway | |||||
| Alzheimers Disease | |||||
| Signalling by NGF | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01821118) Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy. U.S. National Institutes of Health. | ||||
| REF 2 | Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J Mol Biol. 2012 Aug 24;421(4-5):525-36. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.